

产品名称: **BAY 41-2272**

产品别名: **BAY 41-2272**

生物活性:					
Description	BAY 41-2272 is a soluble guanylate cyclases (sGC) activator. Target: guanylate cyclase BAY 41-2272 is a recently introduced novel orally available agent that directly stimulates soluble guanylate cyclase (sGC) and sensitizes it to its physiological stimulator, nitric oxide. BAY 41-2272 is a promising new therapeutic agent that goes beyond current therapeutic agents. BAY 41-2272 acts as an arterial vasodilator, resulting in a reduction of MAP and pulmonary artery pressure and a decrease in SVR and renal vascular resistance. BAY 41-2272 reduces pulmonary capillary wedge pressure in the absence of a decrease in right atrial pressure. [2]				
Solvent&Solubility	In Vitro: DMSO : 17.5 mg/mL (48.56 mM; Need ultrasonic and warming)				
		Mass	1 mg	5 mg	10 mg
	Preparing	Concentration			
		1 mM	2.7748 mL	13.8739 mL	27.7477 mL
	Stock Solutions	5 mM	0.5550 mL	2.7748 mL	5.5495 mL
	10 mM	0.2775 mL	1.3874 mL	2.7748 mL	
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。				
References	[1]. Tuttle TR, et al. The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer Lett. 2016 Jan 28;370(2):279-85. [2]. Boerrigter G, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003 Feb 11;107(5):686-9.				

源叶生物